Pfizer Inc., the American pharmaceutical giant with roots in Germany, collaborated with biotechnology company BioNTech to create the BNT162b2 vaccine that has shown the most successful efficacy results among all the leading candidates in the vaccine race.
22 January 2021
WHO informed on Friday that Pfizer will be providing 40 million doses of Covid-19 vaccine to poor nations.
25 January 2021
Pfizer vaccine has been approved by Australia's medical regulator for provisional use.
December 14 2020
After the two NHS workers suffered allergic reactions the British healthcare regulator issued a warning to people that people with significant allergies should not be taking the vaccine.
December 28 2020
WHO granted emergency validation to Pfizers vaccine.
In India too the authorisation has been granted.
Pfizer: Pfizer COVID vaccine has led to allergic reactions among people who have been administered the vaccine.
● After vaccine administration began in the US, a woman from Alaska has suffered an allergic reaction, after she was given the Pfizer-BioNTech COVID vaccine.
● The adverse reaction in the person, minutes after taking the Pfizer shot on Tuesday, was similar to two cases reported last week in Britain.
● Two people in Britain had experienced a similar allergic reaction post the vaccine administration, after which authorities issued an allergy warning for the Pfizer vaccine use in the country, asking people with existing allergies to avoid getting the jab as of now.
Pfizer: The Pfizer COVID vaccine is likely to be administered to people in the US, starting today.
● After the US FDA granted emergency use authorization to the Pfizer-BioNTech COVID-19 vaccine on Saturday, the first doses of the vaccine distribution are likely to begin on Monday.
● The first shipments of Pfizer and BioNTech's Covid-19 vaccine will leave Kalamazoo, Michigan, on Sunday, reported CNN.
● "We are having this mass casualty event every day here in the US. But now we have this vaccine developed in record time that can, in time, really save us and save our country and save the world from this awful pandemic," emergency physician Dr Leana Wen told CNN's Chris Cuomo moments after the authorization.
Latest Update (8th December): Among many vaccine candidates, the first to seek an emergency approval from India is Pfizer on December 4.
● Pfizer India, which has been developing its vaccine candidate in collaboration with BioNtech, reportedly submitted the application to the Drugs Controller General of India (DCGI) on December 4.
● Meanwhile, the company has already received emergency clearance for the mass distribution of the vaccine in the United Kingdom and Bahrain.
● However, this vaccine candidate needs to be stored at a temperature of -70°C, which is equivalent to an Antarctic winter.
● This poses the biggest challenge for India, as the country will have to completely revamp its cold storage facilities.
● Without an extremely cold storage system, the vaccine may become ineffective within two days.
Latest Update (1st December): The Pfizer vaccine, with 95% efficacy, will not be available in India for long.
● The Pfizer-BioNTech SE coronavirus vaccine, which showed 95 per cent efficacy in clinical trials, is expected to get regulatory approval for distribution from the United Kingdom government as early as next week.
● While British regulators were willing to administer the Pfizer COVID-19 vaccine by December 1 and even informed the National Health Service the same, in India, the review and analysis may take much longer.
● Not only will this breakthrough vaccine be expensive for the Indian common man, it poses a serious difficulty for storage as the vaccine, which uses a novel technology with synthetic mRNA to activate the immune system against the virus, needs to be kept at a temperature of minus 70 degrees Celsius (-94 F) or below.
● As a result, Pfizer’s coronavirus vaccine is highly unlikely to be available at any local pharmacy in India for a long time.
Update (26th November): Those who get the Pfizer vaccine shot will receive daily texts from authorities for follow-ups for the first week.
● The CDC and the US FDA will be jointly sending daily texts to those who are vaccinated for the first week and then weekly texts for six weeks, and monitor side-effects in real time.
Company: Pfizer Inc.
Country of origin : American
● The vaccine elicited high, dose level-dependent SARS-CoV-2-neutralizing titers and RBD-binding IgG concentrations after the second dose.
● potentially be administered safely, with a manageable tolerability profile
● A vaccine jointly developed by Pfizer and BioNTech was 90% effective in preventing Covid-19 infections
● the final stage -- of the new vaccine, BNT162b2, began in late July and has enrolled 43,538 participants to date, 90% of whom have received a second dose of the vaccine candidate as of November 8.
● generally mild to moderate, with occasional severe events (Grade 3) of flu-like symptoms and injection site reactions
● cold and hot rushes
● severe fevers of 39°C to 40°C.
Pfizer and BioNTech have concluded the Phase 3 study of their vaccine candidate BTN162b2, meeting all the primary efficacy endpoints with a claimed efficacy percentage of 95. Primary efficacy analysis reveals that BNT162b2 is 95% effective against COVID-19 starting 28 days after the first dose; 170 confirmed cases of COVID-19 were assessed, with 162 in the placebo group compared to 8 in the vaccine group.The companies intend to send EUA data to the FDA within days and share it with other regulatory agencies worldwide.
They plan to manufacture up to 50 million doses of vaccines worldwide by 2020 and up to 1.3 billion by the end of 2021.